Utah approves AI system to prescribe acne treatments without prior doctor sign-off

For the first time in the United States, and possibly anywhere in the world, an artificial intelligence system has been cleared to write prescriptions without a doctor approving each one in advance. That is not a future ambition. It is already happening in Utah.

The system is built by Nolla Health, a New York-based health technology company. In October 2026, the company received regulatory approval from Utah's Office of Artificial Intelligence Policy to begin issuing initial acne prescriptions autonomously, within a controlled pilot programme. Patients access the service through the Nolla Derm app. They complete a 10 to 15 minute questionnaire and a facial scan, and the system selects a treatment from a predefined list of physician-approved topical options. A prescription can be generated within minutes.

But the system is not operating without any oversight. Nolla has designed a phased approach that tightens physician review over time. In the first phase, covering the first 100 patients, a doctor approves every prescription individually. In the second phase, covering the next 500 patients, the AI prescribes autonomously while a physician reviews the decisions at the end of each day. By the third phase, physicians review only a sample of prescriptions, once a week.

How does it work?

The technology combines structured patient intake data with analysis of facial images. Nolla says its platform uses multimodal machine-learning models, including vision transformers, trained on more than three million labeled clinical cases. For this pilot, though, the system's choices are deliberately narrow. It cannot write prescriptions for all available drugs. It is restricted to a short list of physician-approved topicals and predefined treatment pathways.

'The AI can't improvise. It can only choose from a short list of physician-approved topical treatments,' said Dr. Zaid Fadul, Nolla Health's chief medical advisor. 'The moment a patient falls outside those limits, it stops and hands them to a doctor.'

After receiving a prescription, patients can choose home delivery or pharmacy pickup. The app also uses daily skin scans to monitor progress, with treatment plans reviewed monthly based on the patient's response. A licensed physician is available for direct consultation when needed. The pilot is open to Utah residents aged 18 and older, and the service starts at $4.99 per month.

Why does it matter?

The distinction from conventional telehealth is significant. Most digital health platforms collect symptoms or help clinicians organise information, but a licensed doctor still makes the final call. Nolla's model is different. Within defined limits, the AI makes the prescribing decision itself.

Nolla says licensed clinicians agree with the system's treatment recommendations in more than 96 percent of real-world cases. The company notes that disagreements have generally involved minor adjustments, such as changing the concentration of a topical medication. That figure comes from Nolla itself and has not been independently verified.

For health systems across the GCC, where dermatology access outside major urban centres remains inconsistent, a model like this is worth watching closely. Saudi Arabia's Vision 2030 and the UAE's national AI strategy both identify autonomous health services as a priority area. The question is not whether AI will enter clinical decision-making in this region. It already has. The question is at what pace regulators will allow it to take over steps that currently require a physician.

The context

Utah has been one of the more active U.S. states in creating legal space for AI experimentation in healthcare. Its regulatory sandbox model allows companies to test applications that do not fit neatly into existing frameworks, under monitored conditions. That approach mirrors discussions happening at health ministries across the Gulf, where policymakers are weighing how to attract health technology investment without compromising patient safety.

So what does this pilot actually signal? It suggests that regulators, at least in some jurisdictions, are prepared to allow AI systems to take on prescribing authority for low-risk, well-defined conditions. Acne is a sensible starting point. The treatment options are limited, the risk of serious harm is low, and the condition is common enough to generate meaningful data quickly.

Still, the broader implications extend well beyond dermatology. If this model proves safe and effective at scale, it will build the case for extending autonomous AI prescribing to other routine conditions. That is a shift that healthcare leaders, regulators, and clinicians across the Arab world will need to prepare for, whether they see it as an opportunity or a risk.

• The Nolla Derm app is available to Utah residents aged 18 and older
• Patients complete a questionnaire and facial scan before the AI selects a treatment
• Prescriptions are restricted to a physician-approved list of topical acne treatments
• A licensed physician is available when the AI cannot confidently select a treatment
• The service starts at $4.99 per month; the app has been downloaded more than 175,000 times across 44 U.S. states